...
首页> 外文期刊>Current Eye Research >Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy.
【24h】

Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy.

机译:增生性糖尿病视网膜病变玻璃体切除术后玻璃体出血的原因和处理。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To analyze the reasons for postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy (PDR), and to evaluate the effects of retreatment. Design: Retrospective, nonrandomized, observational case series. METHODS: Three hundred and fifteen eyes of 302 consecutive patients underwent primary standard three-port vitrectomy with 20-gauge instruments for complications of PDR from 2000 to 2006. One hundred and forty-two patients were male, and 160 were female. The age ranged from 38 to 72 years with a mean of 56 years. There were 32 eyes which developed postvitrectomy vitreous hemorrhage during follow-up. The mean follow-up was 12 months with a range from 3 to 48 months. RESULTS: Of 315 eyes with PDR and receiving pars plana vitrectomy, 32 eyes had postvitrectomy vitreous hemorrhage. The onset of recurrent vitreous hemorrhage ranged from 1 to 210 days with an average of 51 days. The reasons for postvitrectomy vitreous hemorrhage in PDR mainly included fibrovascular ingrowth at sclerotomy sites (9 eyes), residual or recurrent neovascular membrane on the optic nerve (6 eyes), insufficient retinal photocoagulation (7 eyes), residual and recurrent epiretinal proliferative membrane (3 eyes), retinal vein occlusion (2 eyes), postoperative low intraocular pressure (2 eyes), and ocular trauma (3 eyes). The visual acuity increased in 31 eyes (96.88%), and decreased in 1 eye (3.12%) after retreatment. The postoperative complications following the treatment of recurrent vitreous hemorrhage mainly included posterior synechia of the iris (3 eyes), nucleus sclerosis (18 eyes), and delayed healing of corneal epithelium (3 eyes). CONCLUSION: Vitrectomy is a safe and effective method for treating PDR. Appropriate and complete analysis of postvitrectomy vitreous hemorrhage can significantly improve the primary treatment effects for PDR.
机译:目的:分析增生性糖尿病视网膜病变(PDR)玻璃体切除术后玻璃体出血的原因,并评估其再治疗的效果。设计:回顾性,非随机,观察性病例系列。方法:2000年至2006年,对302例连续患者的315眼进行了一次原发性标准三端口玻璃体切除术,使用20规仪器对PDR进行了并发症。男性142例,女性160例。年龄从38岁到72岁不等,平均年龄为56岁。随访期间有32只眼发生玻璃体切除术后玻璃体出血。平均随访时间为12个月,范围为3到48个月。结果:315眼PDR并接受了平面玻璃体切除术,其中32眼发生了玻璃体切除术后玻璃体出血。复发性玻璃体出血的发作时间为1至210天,平均51天。 PDR玻璃体切除术后玻璃体出血的原因主要包括巩膜切开处的纤维血管向内生长(9眼),视神经上残留或复发的新生血管膜(6眼),视网膜光凝不足(7眼),残留和复发性视网膜前增生膜(3)。眼),视网膜静脉阻塞(2眼),术后低眼压(2眼)和眼外伤(3眼)。复治后视力增加31眼(96.88%),下降1眼(3.12%)。玻璃体大出血治疗后的术后并发症主要包括虹膜后粘连(3眼),核硬化(18眼)和角膜上皮延迟愈合(3眼)。结论:玻璃体切除术是治疗PDR的一种安全有效的方法。玻璃体切除术后玻璃体出血的适当和完整分析可以显着改善PDR的主要治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号